Intensified conditioning regimens with total marrow irradiation/etoposide/cyclophosphamide and busulfan/etoposide/cyclophosphamide overcome the impact of pre‐transplant minimal residual disease on outcomes in high‐risk acute lymphoblastic leukemia patients in complete remission

Ähnliche Einträge

• Prospective phase II study of allogeneic hematopoietic stem cell transplantation with targeted busulfan, fludarabine, and etoposide conditioning in pediatric acute lymphoblastic leukemia
  von: Kyung Taek Hong, et al.
  Veröffentlicht: (2024)
• Haploidentical hematopoietic stem cell transplantation with busulfan, cyclophosphamide, and fludarabine conditioning for X‐linked adrenal cerebral leukodystrophy
  von: Yao Chen, et al.
  Veröffentlicht: (2024)
• Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone ( BV ‐ CHEP ) for the treatment of aggressive adult T‐cell leukaemia/lymphoma
  von: Christopher Dittus, et al.
  Veröffentlicht: (2025)
• A complete oral regimen for induction therapy of patients with high‐risk APL: An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy
  von: Fei‐Fei Tang, et al.
  Veröffentlicht: (2024)
• Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study
  von: Peña, M., et al.
  Veröffentlicht: (2026)